Clinicopathological features of primary seminal vesicle adenocarcinoma: A report of 4 cases and review of the literature.
- Author:
Jia-Ning GUO
1
;
Hui LI
2
;
Zhan-Dong HU
3
;
En-Li LIANG
1
;
Ji-Wu CHANG
1
Author Information
1. Tianjin Research Institute of Urology / Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.
2. Department of Clinical Laboratory, Tianjin Tumor Hospital, Tianjin 300000, China.
3. Department of Pathology, Tianjin First Central Hospital, Tianjin 300000, China.
- Publication Type:Case Reports
- Keywords:
clinicopathological features;
diagnosis;
immunohistochemistry;
treatment;
seminal vesicle adenocarcinoma
- MeSH:
Adenocarcinoma;
chemistry;
pathology;
surgery;
Biopsy;
CA-125 Antigen;
analysis;
Diagnosis, Differential;
Genital Neoplasms, Male;
chemistry;
pathology;
surgery;
Humans;
Immunohistochemistry;
Male;
Neoplasm Recurrence, Local;
Pelvic Neoplasms;
diagnostic imaging;
Prostate-Specific Antigen;
analysis;
Prostatectomy;
Seminal Vesicles;
pathology;
surgery
- From:
National Journal of Andrology
2017;23(7):639-645
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinicopathological characteristics, diagnosis, and treatment of primary seminal vesicle adenocarcinoma (SVAC).
METHODS:We analyzed the clinical data and clinicopathological characteristics of 4 cases of primary SVAC treated in the Department of Urology of the Second Hospital of Tianjin Medical University and reviewed relevant literature.
RESULTS:All the 4 patients were treated by open radical resection of the seminal vesicle and prostate and pathologically diagnosed with SVAC. Preoperative prostatic biopsy had shown 1 of the cases to be negative, while preoperative CT and transrectal ultrasound had revealed a huge pelvic cystic neoplasm in another patient. Immunohistochemistry manifested that the 4 cases were all negative for prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and cytokeratin 20 (CK20), but positive for cancer antigen 125 (CA125) and CK7. All the patients recovered smoothly after surgery and experienced no recurrence or metastasis during 154, 41, 20, and 12 months of follow-up.
CONCLUSIONS:Primary seminal vesicle carcinoma is extremely rare and presents in an advanced stage. Immunohistochemistry plays a valuable role in its differential diagnosis. Various combinations of radical surgery, radiotherapy, androgen-deprivation therapy, and chemotherapy are recommended for the treatment of the disease.
